Cronos Group (TSE:CRON) Given a C$4.25 Price Target by Canaccord Genuity Group Analysts

Cronos Group (TSE:CRON) received a C$4.25 price target from analysts at Canaccord Genuity Group in a research note issued on Tuesday,BayStreet.CA reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 15.49% from the company’s current price.

Cronos Group Stock Performance

CRON stock traded down C$0.01 during midday trading on Tuesday, hitting C$3.68. 115,034 shares of the stock traded hands, compared to its average volume of 174,464. Cronos Group has a 1-year low of C$2.27 and a 1-year high of C$4.66. The company has a debt-to-equity ratio of 0.17, a current ratio of 24.24 and a quick ratio of 24.01. The firm has a market cap of C$1.41 billion, a P/E ratio of 33.45, a PEG ratio of 0.12 and a beta of 1.13. The stock’s fifty day simple moving average is C$3.68 and its 200-day simple moving average is C$3.49.

Cronos Group (TSE:CRON) last issued its quarterly earnings results on Thursday, November 6th. The company reported C$0.07 EPS for the quarter. The company had revenue of C$50.60 million during the quarter. Cronos Group had a negative net margin of 42.65% and a negative return on equity of 4.40%. On average, analysts expect that Cronos Group will post -0.26 earnings per share for the current year.

Cronos Group Company Profile

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.